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Abstract
A case of a 13 year old girl who manifested
hyperprolactinaemia and galactorrhea induced by Omeprazole,
a commonly used proton pump inhibitor is presented.
Introduction
Hyperprolactinaemia is a condition of elevated serum
prolactin levels, manifesting as galactorrhoea and menstrual
irregularities in women and erectile dysfunction and decreased
libido in men. Hyperprolactinaemia has a long list of causes
including physiological, pathological and pharmacological.1,2
Drug induced hyperprolactinaemia is common and a number
of drugs have been identified as the cause. e.g.
antiphsychotics, antidepressants, H2 receptor antagonist,
antiandrogens, estrogen, prokinetics, anticonvulsants, opiates
and cholinomimetics. These drugs raise the serum prolactin to
a level that is frequently associated with symptoms.1-5
We describe here a case of hyperprolactinaemia
presenting with galactorrhea induced by Omeprazole (losec) a
proton pump inhibitor.
This to our knowledge has not been reported before.
Case Report
A 13 year old girl presented to her physician with a
history of migranous headache and was prescribed mefenamic
acid. Other than these bouts of headache for last 3 months, she
had no active medical issues. On taking mefenamic acid she
developed dyspeptic symptoms and was found helicobacter
antibody positive and was prescribed Omeprazole. After 4
days of treatment with Omeprazole 20mg BD, she developed
bilateral galactorrhea. Her prolactin level was found to be
288ng/ml (normal being 2.7-22.4ng/ml). On detailed
interrogation she refused to have taken any other drugs in
particular antiemetics or H2 receptor antagonists. An MRI of
hypothalamo-pituitary area revealed a bulky pituitary
probably due to pubertal change. She was given a course of
anti helicobacter regimen and Omeprazole was discontinued.
The galactorrhea resolved and three weeks later her serum
prolactin levels returned to 17.5ng/ml (normal).
Considering the temporal relationship with
omeprazole, with the patient and parent's consent, she was
rechallenged with omeprazole after six weeks and her serum
prolactin level was checked again. The serum prolactin level
was increased from a base line of 26.6 to 70ng/ml and returned
back to normal in 2 weeks after withdrawal.
As part of laboratory work up, serum calcium,
phosphorus, gastrin was reported normal.
Later, she reported with a bout of headache to some
other centre and was given injection Domperidone and tablets
for nausea as take home medication. Forty eight hours later
she again developed galactorrhea and her domperidone was
discontinued. This time her prolactin level was 161ng/ml. She
remained normal with episodes of headache and nausea,
which used to settle with acetaminophen and NSAID,
alongwith antacids, sucralfate and ranitidine which was
tolerated well.
After about six months she again developed a severe
bout of headache with nausea, vomiting and dizziness and
attended a nearby medical centre where she was given
injection diclofenac. On insistence by her parents about the
past medical history of galactorrhea induced by omeprazole
(losec), this time she was prescribed lansoprazole instead of
omeprazole. Three days later she again developed
galactorrhea and her serum prolactin was 49.7ng/ml which
returned to normal in a week after stopping lansoprazole.
These three documented instances of
hyperprolactinemia by proton pump inhibitors is to our
knowledge, has not been reported before.
Discussion
Hyperprolactinemia, a very common biochemical
abnormality, is frequently associated with the use of certain
medications. There is a long list of medications that are
associated with a rise in serum prolactin and symptoms of
hyperprolactinemia.1-5
Hyperprolactinemia induced by medication should
return to normal after the withdrawal of the offending drug. In
this case the administration of proton pump inhibitor provoked
a rise in serum prolactin level, followed by a return towards
the baseline after its discontinuation. Although proton pump
inhibitors are generally well tolerated and they are the most
commonly prescribed classes of medication in the treatment of
acid peptic disease,6 an important adverse effect is a rise in
serum prolactin level.
To our knowledge this is the first case report
incriminating the proton pump inhibitors as a cause of
symptomatic hyperprolactinemia. Hyperprolactinemia
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induced by medication does not need to be managed with
dopamine agonists like cabergoline or bromocriptine, as in
the case of hyperprolactinemia caused by some
pathological cause.1
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